Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 7;2:7. doi: 10.1038/s41698-018-0051-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — MPAS is a negative prognostic for survival in colorectal cancer. a Multivariate Cox proportional hazard regression models for both metastatic CRC samples (mCRC) and for samples from AVANT adjuvant phIII trial parameterized using MPAS, KRAS, and BRAF mutation status (mCRC) in addition to MSI status and treatment condition; FOLFOX vs. XELOX (Tx FOL vs. XEL) and Avastin for the AVANT samples. Hazard ratios, 95% confidence intervals, and associated P-values associated with each feature are shown. Kaplan–Meier curves of overall survival (OS) were plotted using the median value of MPAS to classify b mCRC patients or c AVANT patients as either MAPK-high vs. -low for all patients or for patients with BRAF mutations. Cox proportional hazard regression models were used to fit each treatment arm separately, using MPAS as a univariate predictor of overall survival. Hazard ratios, 95% confidence intervals, and associated P-values for MPAS as a univariate predictor are shown within each graph. Kaplan–Meier scans showing hazard ratios of overall survival (OS) over a range of thresholds for classifying MAPK-high vs. -low patients from b mCRC patients or c AVANT patients are also shown. Blue line represents the hazard computed at each threshold, and black lines show 95% confidence intervals